What is NDC 50242-096?

50242-096 is the product NDC for Vabysmo (faricimab), Faricimab 6 mg/.05mL injection, solution, listed with the FDA by Genentech, Inc.. It has 4 package NDCs, shown above in 10- and 11-digit form.

Genentech, Inc., NDC labeler code 50242. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Vabysmo?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Yes: J2777, Injection, faricimab-svoa, 0.1 mg.

Vabysmo NDC 50242-096 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)50242-096Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50242-0096Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
50242-096-01	50242009601	1 VIAL in 1 CARTON (50242-096-01) / .05 mL in 1 VIAL (50242-096-03)Marketed from Jan 28, 2022
50242-096-06	50242009606	1 SYRINGE in 1 CARTON (50242-096-06) / .05 mL in 1 SYRINGEMarketed from Jul 3, 2024
50242-096-45	50242009645	1 SYRINGE in 1 CARTON (50242-096-45) / .05 mL in 1 SYRINGEMarketed from Jul 3, 2024 · Sample package
50242-096-86	50242009686	1 VIAL in 1 CARTON (50242-096-86) / .05 mL in 1 VIAL (50242-096-77)Marketed from Jan 28, 2022 · Sample package

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Vabysmo
Generic name (nonproprietary): faricimab
Active ingredients: Faricimab — 6 mg/.05mL
Dosage form: Injection, Solution
Route: Intravitreal
Labeler: Genentech, Inc.NDC labeler code 50242
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761235
Marketing start: Jan 28, 2022
Listing expires: Dec 31, 2027
Identifiers: Product ID 50242-096_d03c8813-cfdd-498f-9085-44e3d8436620SPL ID d03c8813-cfdd-498f-9085-44e3d8436620SPL set ID 04cc9ef7-c02a-4e92-a655-0062674e8487RxCUI 2591588, 2591594, 2692684, 2692688UNII QC4F7FKK7I

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeMed-Code curated

J2777 — Injection, faricimab-svoa, 0.1 mg

Billing unit: 0.1 mg. Units on the claim = dose given ÷ 0.1 mg.

Administration

Intravitreal injection procedure (CPT 67028)

The intravitreal injection is reported as a separate procedure from the drug supplied.

How CPT relates to drug billing

NDC on a medical claim

N450242009601 followed by a unit qualifier and the quantity

Package 50242-0096-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 15, 2026.

Indications (excerpt from the label)

VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor indicated for the treatment of patients with: VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (nAMD) ( 1.1 ) Diabetic Macular Edema (DME) ( 1.2 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.3 ) 1.1 Neovascular (wet) Age-Related Macular Degeneration (nAMD) 1.2 Diabetic Macular Edema (DME) 1.3 Macular Edema Following Retinal Vein Occlusion (RVO)

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 50242-096

What is NDC 50242-096?: 50242-096 is the product NDC for Vabysmo (faricimab), Faricimab 6 mg/.05mL injection, solution, listed with the FDA by Genentech, Inc.. It has 4 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Vabysmo (Faricimab).
What is the active ingredient?: Faricimab.
Who is the labeler?: Genentech, Inc., NDC labeler code 50242. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Vabysmo?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Yes: J2777, Injection, faricimab-svoa, 0.1 mg. See Billing references above.

Vabysmo (Faricimab) NDC 50242-096